Advertisement

Journal of Neurology

, Volume 260, Issue 2, pp 454–457 | Cite as

Parkinson’s disease-like midbrain hyperechogenicity is frequent in amyotrophic lateral sclerosis

  • Panteha Fathinia
  • Andreas Hermann
  • Ulrike Reuner
  • Jan Kassubek
  • Alexander Storch
  • Albert C. Ludolph
Original Communication

Abstract

Clinical and neuroimaging data suggest impairment of the nigrostriatal system in amyotrophic lateral sclerosis (ALS). We thus hypothesized whether Parkinson’s disease (PD)-like midbrain sonography findings are also present in ALS. Eighty-six patients with the diagnosis of possible or definite ALS according to revised El Escorial criteria were examined by transcranial B-mode sonography compared to 76 age- and gender-matched controls and 33 PD patients. Hyperechogenic areas of the midbrain representing the substantia nigra were measured planimetrically using standard protocols. In subjects with sufficient temporal acoustic bone windows, mean midbrain hyperechogenic areas were significantly higher in ALS (0.251 ± 0.104 cm2) and PD patients (0.286 ± 0.078 cm2) compared to controls (0.091 ± 0.054 cm2) with no significant difference between ALS and PD patients (one-way ANOVA: F value = 94.3; P < 0.0001). Sixty-seven percent (95 % CI 57–78 %) of ALS patients and 84 % (95 % CI 71–97 %) of PD patients displayed abnormal midbrain hyperechogenic areas (P = 0.383 for group comparison, χ2 test). No correlations of hyperechogenic area sizes in ALS patients were found in regard to age, gender, ALS subtype (bulbar versus spinal form) or ALS-FRS-R score. In summary, we observed hyperechogenicity of the substantia nigra in patients with sporadic ALS with a frequency similar to that in PD and higher than in all other movement disorders. These findings are important for the diagnosis and differential diagnosis of PD and ALS alike.

Keywords

Amyotrophic lateral sclerosis Substantia nigra Parkinson’s disease Symptomatic therapy 

Notes

Acknowledgments

We thank all the patients who participated in this study and acknowledge the enthusiastic help of Tordis Leimert.

Conflicts of interest

None of the authors reports any disclosures for this study.

Ethical standard

The study was approved by the local ethics committees of the Universities of Ulm and Dresden.

References

  1. 1.
    Becker G, Seufert J, Bogdahn U, Reichmann H, Reiners K (1995) Degeneration of substantia nigra in chronic Parkinson’s disease visualized by transcranial color-coded real-time sonography. Neurology 45(1):182–184PubMedCrossRefGoogle Scholar
  2. 2.
    Berg D, Godau J, Walter U (2008) Transcranial sonography in movement disorders. Lancet Neurol 7(11):1044–1055. doi: 10.1016/S1474-4422(08)70239-4 PubMedCrossRefGoogle Scholar
  3. 3.
    Gaenslen A, Unmuth B, Godau J, Liepelt I, Di Santo A, Schweitzer KJ, Gasser T, Machulla HJ, Reimold M, Marek K, Berg D (2008) The specificity and sensitivity of transcranial ultrasound in the differential diagnosis of Parkinson’s disease: a prospective blinded study. Lancet Neurol 7(5):417–424. doi: 10.1016/S1474-4422(08)70067-X PubMedCrossRefGoogle Scholar
  4. 4.
    Berg D, Roggendorf W, Schroder U, Klein R, Tatschner T, Benz P, Tucha O, Preier M, Lange KW, Reiners K, Gerlach M, Becker G (2002) Echogenicity of the substantia nigra: association with increased iron content and marker for susceptibility to nigrostriatal injury. Arch Neurol 59(6):999–1005 noc10166 [pii]PubMedCrossRefGoogle Scholar
  5. 5.
    Pradat PF, Bruneteau G, Munerati E, Salachas F, Le Forestier N, Lacomblez L, Lenglet T, Meininger V (2009) Extrapyramidal stiffness in patients with amyotrophic lateral sclerosis. Mov Disord 24(14):2143–2148. doi: 10.1002/mds.22762 PubMedCrossRefGoogle Scholar
  6. 6.
    Kato S, Oda M, Tanabe H (1993) Diminution of dopaminergic neurons in the substantia nigra of sporadic amyotrophic lateral sclerosis. Neuropathol Appl Neurobiol 19(4):300–304PubMedCrossRefGoogle Scholar
  7. 7.
    Borasio GD, Linke R, Schwarz J, Schlamp V, Abel A, Mozley PD, Tatsch K (1998) Dopaminergic deficit in amyotrophic lateral sclerosis assessed with [I-123] IPT single photon emission computed tomography. J Neurol Neurosurg Psychiatry 65(2):263–265PubMedCrossRefGoogle Scholar
  8. 8.
    Hideyama T, Momose T, Shimizu J, Tsuji S, Kwak S (2006) A positron emission tomography study on the role of nigral lesions in parkinsonism in patients with amyotrophic lateral sclerosis. Arch Neurol 63(12):1719–1722PubMedCrossRefGoogle Scholar
  9. 9.
    Walter U, Dressler D, Wolters A, Probst T, Grossmann A, Benecke R (2004) Sonographic discrimination of corticobasal degeneration vs progressive supranuclear palsy. Neurology 63(3):504–509PubMedCrossRefGoogle Scholar
  10. 10.
    Kasarskis EJ, Tandon L, Lovell MA, Ehmann WD (1995) Aluminum, calcium, and iron in the spinal cord of patients with sporadic amyotrophic lateral sclerosis using laser microprobe mass spectroscopy: a preliminary study. J Neurol Sci 130(2):203–208PubMedCrossRefGoogle Scholar
  11. 11.
    Pinkhardt EH, Sperfeld AD, Gdynia HJ, Ludolph AC, Kassubek J (2009) The combination of dopa-responsive parkinsonian syndrome and motor neuron disease. Neurodegener Dis 6(3):95–101. doi: 10.1159/000207795 PubMedCrossRefGoogle Scholar
  12. 12.
    Danzeisen R, Schwalenstoecker B, Gillardon F, Buerger E, Krzykalla V, Klinder K, Schild L, Hengerer B, Ludolph AC, Dorner-Ciossek C, Kussmaul L (2006) Targeted antioxidative and neuroprotective properties of the dopamine agonist pramipexole and its nondopaminergic enantiomer SND919CL2x [(+)2-amino-4,5,6,7-tetrahydro-6-l-propylamino-benzathiazole dihydrochloride]. J Pharmacol Exp Ther 316(1):189–199. doi: 10.1124/jpet.105.092312 PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2012

Authors and Affiliations

  • Panteha Fathinia
    • 1
  • Andreas Hermann
    • 2
    • 3
  • Ulrike Reuner
    • 2
  • Jan Kassubek
    • 1
  • Alexander Storch
    • 2
    • 3
  • Albert C. Ludolph
    • 1
  1. 1.Department of NeurologyUniversity of UlmUlmGermany
  2. 2.Division of Neurodegenerative Diseases, Department of NeurologyDresden University of TechnologyDresdenGermany
  3. 3.German Centre for Neurodegenerative Diseases (DZNE) DresdenDresdenGermany

Personalised recommendations